ments include (but are not limited to) statements about expected benefits and risks associated with the Further Increased Offer; projections or expectations of profit attributable to shareholders; anticipated provisions or write-downs, economic profit, dividends, capital structure or any other financial items or ratios; statements of plans, objectives or goals of Elan, the Elan Group, RP Management or Royalty Pharma following the Further Increased Offer; statements about the future trends in interest rates, liquidity, foreign exchange rates, stock market levels and demographic trends and any impact that those matters may have on Elan, the Elan Group, RP Management or Royalty Pharma following the Further Increased Offer; statements concerning any future Irish, US or other economic environment or performance; statements about strategic goals, competition, regulation, regulatory approvals, dispositions and consolidation or technological or regulatory developments; and statements of assumptions underlying such statements.
Forward looking statements only speak as of the date on which they are made, and the events discussed in this announcement may not occur. Subject to compliance with applicable law and regulation, Royalty Pharma is not under any obligation to update publicly or revise forward looking statements, whether as a result of new information, future events or otherwise.
Rule 8 - Dealing Disclosure Requirements
Under the provisions of Rule 8.3 of the Irish Takeover Rules, if any person is, or becomes, "interested" (directly or indirectly) in 1% or more of any class of "relevant securities" of Elan, all "dealings" in any "relevant securities" of Elan (including by means of an option in respect of, or a derivative referenced to, any such "relevant securities") must be publicly disclosed by not later than 3.30 pm (Irish time) on the "business day" following the date of the relevant transaction. This requirement will continue until the date on wPage: 1 2 3 4 5 6 7 8 9 10 11 Related biology technology :1
. Royalty Pharma Increases Offer to Acquire Elan to $13.00 Per Share in Cash Plus a Contingent Value Right of Up to $2.50 Per Share2
. Royalty Pharma Statement Regarding Elan Law Suits3
. Cadwalader Advises Elan Corporation in Billion Dollar Royalty Deal4
. Royalty Pharma Statement Regarding Elan Proposal5
. PDL BioPharma Provides Third Quarter 2012 Royalty Revenue Guidance of $85 Million6
. Cowen Healthcare Royalty Partners Raises $1 Billion7
. Smart Consulting Group and The Catalyst Group Form Alliance to Supply Quality Compliance Consulting Services For the Pharmaceutical Industry8
. Pursuit's Elissa Guerra and Eunjoo Pluenneke to Present on Mobile Strategy at Digital Pharma West Conference9
. MEI Pharma Adds Former YM BioSciences CEO Nick Glover To Board Of Directors10
. Frost & Sullivan Recognizes Sciformixs Continued Growth in the Increasingly Complex Pharmaceutical KPO Market11
. Auxilium Pharmaceuticals, Inc. To Present At The Goldman Sachs 34th Annual Global Healthcare Conference